CN105601524A - Preparation method of LCZ696 key intermediate - Google Patents

Preparation method of LCZ696 key intermediate Download PDF

Info

Publication number
CN105601524A
CN105601524A CN201610151805.5A CN201610151805A CN105601524A CN 105601524 A CN105601524 A CN 105601524A CN 201610151805 A CN201610151805 A CN 201610151805A CN 105601524 A CN105601524 A CN 105601524A
Authority
CN
China
Prior art keywords
formula
biphenyl
reaction
methyl
grams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610151805.5A
Other languages
Chinese (zh)
Other versions
CN105601524B (en
Inventor
邱小龙
胡林
邹平
王东辉
刘呈昭
邓贤明
游正伟
江中兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Huiju Pharmaceutical Co ltd
Original Assignee
Wisdom Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisdom Pharmaceutical Co Ltd filed Critical Wisdom Pharmaceutical Co Ltd
Priority to CN201610151805.5A priority Critical patent/CN105601524B/en
Publication of CN105601524A publication Critical patent/CN105601524A/en
Application granted granted Critical
Publication of CN105601524B publication Critical patent/CN105601524B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
    • C07C1/26—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only halogen atoms as hetero-atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/36—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C07C67/327—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by elimination of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides preparation of an LCZ696 key intermediate and relates to a preparation method of the LCZ696 key intermediate (4S,2R)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride. Two chiral centers of the (4S,2R)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride prepared by adopting the preparation method provided by the invention are respectively from chiral fragments, usage of expensive metal catalysts and chiral ligands which are difficult to commercially purchase in bulk is avoided, and commercialized production can be easily realized.

Description

The preparation of LCZ696 key intermediate
Technical field
The invention belongs to medical chemistry field, relate to LCZ696 key intermediate (4S, 2R)-5-([1,1'-biphenyl]-4-Base) preparation method of-4-amino-2-methyl valerate hydrochloride.
Background technology
LCZ696 is a kind of angiotensin receptor and enkephalinase double inhibitor, English Entresto by name,Within 2015, FDA ratifies this medicine as angiotensin ii receptor blocker based on its excellent clinical test results, to reduce windThe cardiovascular death of danger heart failure patient and hospitalization chronic heart failure (NYHAII-IV level) and LVEF reduceLCZ696. LCZ696 is drug for hypertension Valsartan and a kind of novel antihypertensive medicament that has lost patent protection at presentThe combination drug of Sacubitril (enkephalinase inhibitor), its structural formula is as follows:
In the preparation technology of LCZ696, relate to key intermediate (2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-Synthesizing of methylpent acid esters. Patent WO2014/032627 and patent EP1903027 disclose (2R, 4S)-5-([1,1'-connectionBenzene]-4-yl) preparation method of-4-amino-2-methyl pentanoate derivant. The method is using 4-bromo biphenyl as starting material,After preparing RMgBr and chirality (S)-epoxychloropropane or (S)-epoxy-tertbutyl ether reaction, obtain corresponding hydroxy compoundThing; Under the effect of diethyl azodiformate/triphenylphosphine, Mitsunobu to occur anti-for hydroxy compounds and succinimide subsequentlyShould obtain pyrrolidines-2 of configuration inversion, 5-diketone intermediate; The latter uses concentrated hydrochloric acid deprotection base and under alkali conditionOccur to obtain corresponding (R)-3-([1,1'-biphenyl]-4-yl) 2-aminopropan-1-ols hydrochloride after nucleophilic substitution; This saltAmino to use the product oxidation of primary hydroxyl under NaClO/TEMPO condition after Boc protection be corresponding aldehyde product, occur subsequentlyAfter Wittig reaction and use LiOH hydrolysis ethyl ester, obtain (R)-5-biphenyl-4-base-4-Boc amino-2-methyl penta-2-olefin(e) acid;The latter is at metallic catalyst [RuI2(p-cymene)]2With under the effect of chiral ligand mandyphosSL-M004-1, occur not rightClaim hydrogenating reduction, obtain (2R, 4S)-5-biphenyl-4-base-4-Boc amino-2-methyl valeric acid; It is complete that ethyl esterization is carried out in this acid subsequentlyBecome the preparation of (2R, 4S)-5-biphenyl-4-amino-2-methyl pentanoic acid ethyl ester. This route not only synthesis step is many, and processIn used the metallic catalyst [RuI that very expensive and commercialization is difficult for a large amount of buyings2(p-cymene)]2And chiral ligandMandyphosSL-M004-1, therefore suitability for industrialized production is restricted. Patent WO2014/032627 and patent EP1903027 closeBecome route as follows:
Summary of the invention
Through a large amount of research and development experiments, the present invention develops preparation (2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-ammoniaThe variation route of base-2 methyl valeric acid ester, its reaction equation is as follows:
。
Technical characterictic of the present invention is as follows:
1, initiation material 4-bromo biphenyl (formula I) generates the THF solution of 4-xenyl lithium (formula II) under the effect of n-BuLi, shouldSolution is direct and chirality (S)-epoxy halogenopropane (formula III) reaction subsequently, generates (S)-1-([1,1'-biphenyl]-4-yl)-3-Halo-propyl-2-alcohol (formula IV);
Wherein in formula III, IV, X is halogen, preferably chlorine.
2, the hydroxyl of (S)-1-([1,1-biphenyl]-4-yl)-3-halo-propyl-2-alcohol (formula III) uses silicon protecting group to enterRow protection, preparation (S)-1-([1,1-biphenyl]-4-yl)-3-halo-2-siloxy propane (formula V);
Wherein to react the silica reagent using be tert-butyl chloro-silicane or tert-butyl diphenyl chlorosilane to this step;
R in formula V1TBS or TBDPS protecting group.
3, (S)-1-([1,1'-biphenyl]-4-yl)-3-halo-2-siloxy propane (formula V) does the condition of solvent at THFUnder, add magnesium metal to prepare RMgBr (S)-1-([1,1'-biphenyl]-4-yl)--2-siloxy propane-3-magnesium halide (formulaVI) THF solution, then with (the R)-2-fluoroform sulphonyl oxygen propionic acid tert-butyl ester (formula VII) reaction, realization (2R, 4R)-5-(1,1'-xenyl) preparation of-4-siloxy-2 methyl valeric acid tert-butyl ester (formula VIII);
R in its Chinese style VII2Trifyl (CF3SO2-) group;
R in its Chinese style V, VI, VIII1TBS or TBDPS protecting group.
4, (2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-siloxy-2 methyl valeric acid tert-butyl ester (formula VIII) existsUnder TBAF effect, remove the reaction of silicon protecting group and realize (2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-hydroxy-2-methylThe preparation of the valeric acid tert-butyl ester (formula IX);
The solvent that wherein this step reaction is used is selected from THF, EtOAc, Dioxane, CH3CN;
R in its Chinese style VIII1TBS or TBDPS protecting group.
5, (2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-hydroxy-2-methyl valeric acid tert-butyl ester (formula IX) and succinylImines (formula X) or phthalimide (formula XI) generation Mitsunobu reaction realization (2R, 4S)-(5-([1,1'-biphenyl]-4-yl)-2 methyl valeric acid the tert-butyl ester-4-yl)-pyrrolidines-2,5-diketone (formula XII) or (2R, 4S)-5-([1,1'-biphenyl]-4-yl) preparation of-2-methyl-4-phthaloyl imino-valeric acid tert-butyl ester (formula XII)
The phosphonate reagent that wherein Mitsunobu reaction is used is selected from triphenylphosphine or tri-n-butyl phosphine; The coupling reagent usingBe selected from diethyl azodiformate (DEAD) or azoformic acid isopropyl ester (DIAD).
6, (2R, 4S)-(5-([1,1'-biphenyl]-4-yl)-2 methyl valeric acid tert-butyl ester-4-yl)-pyrrolidines-2,5-bis-Ketone (formula XII) or (2R, 4S)-5-([1,1'-biphenyl]-4-yl)-2-methyl-4-phthaloyl imino-valeric acid tert-butyl ester(formula XII) does at alkylol under the condition of solvent and removes succinimide or phthalimide protecting group and uncle with HClButyl protecting group is carried out esterification simultaneously, obtains (2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methyl pentaAcid esters hydrochloride;
The alkylol that wherein reaction is used is selected from methyl alcohol, ethanol.
Use technique of the present invention to synthesize (2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methyl valerateThe step of hydrochloride is shorter, and two chiral centres in product are all to use chirality fragment to introduce, avoided using expensive andCommercialization is difficult for chiral metal catalyst and the chiral ligand reagent of a large amount of buyings, easily realizes the large production of commercialization.
Detailed description of the invention
Can understand more specifically the present invention by the following examples, but it is to illustrate instead of limit the present inventionScope.
Embodiment 1:(S) preparation of-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-alcohol (formula IV, X=Cl)
In 500ml there-necked flask, add 5 grams of 4-bromo biphenyls and anhydrous THF (80ml), after system stirs, be cooled to-78 DEG C,Then in nitrogen protection downhill reaction liquid, slowly add the hexane solution (1.6Minn-hexane, 15ml) of n-BuLi. DripAfter adding, system keeps about-78 DEG C to stir 30 minutes, is slowly warming up to subsequently about-10 DEG C and stirs 2 hours. To reaction bodyIn system, slowly add the THF solution (3 grams, 40mlTHF) of (S)-epoxychloropropane (formula III, X=Cl). Dropwise rear anti-The system of answering is warming up to room temperature reaction 5 hours naturally, with slowly adding 100ml saturated aqueous ammonium chloride to quench in backward reaction systemThe reaction of going out. System adds CH2Cl2Extraction (3 × 50ml), merges organic phase, and anhydrous sodium sulfate is dried organic phase, mistakeFilter, decompression desolvation, residue use column chromatography carry out purifying, (S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-4.5 grams of light yellow solids of propan-2-ol (85%).
Embodiment 2:(S) preparation of-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-alcohol (formula IV, X=Cl)
In 10L glass four-hole bottle, add 200 grams of 4-bromo biphenyls and anhydrous THF (3.2L), after system stirs, be cooled to-78DEG C (dry ice acetone bath), then under nitrogen protection by dropping funel to the hexane solution that slowly adds n-BuLi in reactant liquor(1.6Minn-hexane, 600mL). Dropwise rear system and keep about-78 DEG C to stir 1 hour, slowly heat up subsequentlyTo about-10 DEG C stirrings 4 hours. In reaction system, slowly add the THF of (S)-epoxychloropropane (formula III, X=Cl) moltenLiquid (120 grams, 2LTHF). Dropwise rear reaction system and be naturally warming up to room temperature reaction 7 hours, with slow in backward reaction systemSlowly add 2L saturated aqueous ammonium chloride cancellation reaction. System adds CH2Cl2Extraction (3 × 2L), merges organic phase, anhydrous sulphurAcid sodium is dried organic phase, removes by filter sodium sulphate solid, decompression desolvation, and residue uses column chromatography to carry out pureChange, obtain (S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-172 grams of yellow solids of alcohol (81%).
Embodiment 3:(S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-tertiary butyl dimethyl Si base-propane(formula V, R1=TBS) preparation
In tri-mouthfuls of round-bottomed flasks of 250mL, be equipped with thermometer and magnetic agitation, add (S)-1-([1,1'-biphenyl]-4-yl)-3-8.2 grams of chloro-propyl-2-alcohol (formula IV, X=Cl), then add anhydrous CH2Cl2(80mL) and DMF (2mL). Reactant liquor stirsAfter mixing evenly, add DMAP (50mg), system ice-water bath is cooled to 0 DEG C of left and right. Then by dropping funel in reaction systemSlowly add the CH of TBSCl2Cl2Solution (6 grams, 20mLCH2Cl2), dropping process keeps temperature of reaction system lower than 5 DEG C. DripAfter adding, system is warming up to stirring at room temperature reaction 6 hours naturally. TLC point plate is followed the tracks of removal of solvent under reduced pressure after completion of the reaction, residualExcess column chromatography purification obtains (S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-tertiary butyl dimethyl Si base-the thirdAlkane (light yellow foam-like solid, 10.7 grams, 89%).
Embodiment 4:(S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-tert-butyl diphenyl siloxy-propane(formula V, R1=TBDPS) preparation
In 3L four-hole round-bottomed flask, be equipped with thermometer and mechanical agitation, add (S)-1-([1,1'-biphenyl]-4-yl)-3-chlorine89 grams of generation-propyl-2-alcohol (formula IV, X=Cl), then add anhydrous CH2Cl2(1L) and DMF (20mL). Reactant liquor stirs allAfter even, add DMAP (600mg), system ice-water bath is cooled to 0 DEG C of left and right. Then delay in reaction system by dropping funelSlowly add the CH of TBDPSCl2Cl2Solution (150 grams, 100mLCH2Cl2), dropping process keeps temperature of reaction system lower than 5 DEG C.Dropwise rear system and be naturally warming up to stirring at room temperature reaction 18 hours. TLC point plate is followed the tracks of removal of solvent under reduced pressure after completion of the reaction,Residue column chromatography purification obtain (S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-tert-butyl diphenyl siloxy-Propane (light yellow solid, 144 grams, 82%).
Embodiment 5:(R) the preparation of-2-fluoroform sulphonyl oxygen propionic acid tert-butyl ester (formula VII)
Tri-mouthfuls of round-bottomed flasks of 3L, are equipped with thermometer and magnetic agitation, add 50 grams of D-ALPHA-Hydroxypropionic acid tert-butyl esters (ee > 99%) and anhydrousCH2Cl2(1.2L), system stir after ice-water bath be cooled to 0 DEG C of left and right. In reaction system, add 2,6-lutidines(50mL) after, slowly drip trifluoromethanesulfanhydride anhydride (70mL) by dropping funel, dropping process keeps temperature of reaction system not highIn 5 DEG C. Dropwise rear reaction system stirs 2 hours between 0-5 DEG C. Then in reaction system, slowly add saturated chlorineChange aqueous ammonium (500mL) reaction is carried out to cancellation. Separate CH2Cl2Organic phase, water CH2Cl2Extraction (3 × 800mL),Merge organic phase, 0.5N watery hydrochloric acid (500mL) washs once, and then washs once anhydrous slufuric acid with saturated aqueous common salt (1L)Magnesium is dried organic phase, removes by filter magnesium sulfate solid, decompression desolvation, and residue (81 grams, 85%) does not need purifying straightConnect use.
Embodiment 6:(2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-tertiary butyl dimethyl Si base-2 methyl valeric acidThe tert-butyl ester (formula VIII, R1=TBS) preparation
In 1L flask, add 1 gram of metal magnesium chips and 100ML oxolane, open magnetic agitation. In this reactant liquor, add simultaneouslyA small amount of iodine and 2 grams of (S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-tertiary butyl dimethyl Si base-propane (formula V,R1=TBS) continue to be stirred to grignard reaction start cause. Then, to cause after reaction liquid in slowly add 9 grams (S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-tertiary butyl dimethyl Si base-propane (formula V, R1=TBS) THFSolution (100mL), dropwises rear whole reaction system insulation 35 degree left and right and stirs 2 hours. Subsequently by the Ge Shi examination preparingAgent is transferred in dropping funel, slowly drops to (R)-2-fluoroform sulphonyl oxygen propionic acid tert-butyl ester prepared by 8.5 grams of embodiment 5In the THF solution of (formula VII), dropping process keeps 0 to 5 DEG C of temperature of reaction system. Dropwise rear insulation reaction 2 hours, soBackward reaction system adds saturated NH4The Cl aqueous solution (300ml) cancellation reaction, system is used dichloromethane extraction (3 × 300L),Merge organic phase, 0.5N desalinization of soil by flooding or leaching acid (100mL) is washed once, and then washs once anhydrous sulphur with saturated aqueous common salt (100mL)Acid magnesium is dried organic phase, removes by filter magnesium sulfate solid, decompression desolvation, and residue uses column chromatography purification to obtain(2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-tertiary butyl dimethyl Si base-2 methyl valeric acid tert-butyl ester (formula VIII, R1=TBS) (10.5 grams, 76%).
Embodiment 7:(2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-tert-butyl diphenyl siloxy-2-methylpentTert-butyl acrylate (formula VIII, R1=TBDPS) preparation
In tri-mouthfuls of round-bottomed flasks of 1L, add 2 grams of metal magnesium chips and 150mL oxolane. Under agitation in this reactant liquor, add lessAmount iodine grain and 3 grams of (S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-tertiary butyl dimethyl Si base-propane (formula V,R1=TBDPS) continue to be stirred to grignard reaction start cause. Then, to cause after reaction liquid in slowly add 25 grams(S)-1-([1,1'-biphenyl]-4-yl)-3-chloro-propyl-2-tert-butyl diphenyl siloxy-propane (formula V, R1=TBDPS) THF solution (200mL), dropwises rear whole reaction system insulation 35 degree left and right and stirs 2 hours. To make subsequentlyThe RMgBr of getting ready is transferred in dropping funel, slowly drops to (R)-2-fluoroform sulphonyl oxygen prepared by 24 grams of embodiment 5In the THF solution of the propionic acid tert-butyl ester (formula VII), dropping process keeps 0 to 5 DEG C of temperature of reaction system. Dropwise rear insulation anti-Answer after 4 hours and slowly add saturated NH in reaction system4The Cl aqueous solution (500mL) cancellation reaction, system is used carrene extractionGet (3 × 500L), merge organic phase, 0.5N desalinization of soil by flooding or leaching acid (300mL) is washed once, and then washes with saturated aqueous common salt (300mL)Wash once, anhydrous magnesium sulfate is dried organic phase, removes by filter magnesium sulfate solid, decompression desolvation, and residue usesColumn chromatography purification obtains (2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-tert-butyl diphenyl siloxy-2 methyl valeric acid uncleButyl ester (formula VIII, R1=TBDPS) (22.2 grams, 66.5%).
Embodiment 8:(2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-hydroxy-2-methyl valeric acid tert-butyl ester (formula IX)Preparation
8 grams of (2R, 4R-5-(1,1'-xenyl)-4-tertiary butyl dimethyl Si base-2 methyl valeric acid tert-butyl ester (formula VIII, R1=TBS) be dissolved in THF solution (100mL), stir lower reactant liquor cryosel bath and be cooled to 0 to 5 DEG C, then in this reaction system, delaySlowly add TBAF solution (1MinTHF, 20mL). Dropwise rear reaction system and be naturally warming up to stirring at room temperature 12 hours. InsteadThe system of answering adds saturated NH4The Cl aqueous solution (100mL) cancellation reaction, system is used dichloromethane extraction (3 × 100L). MergeOrganic phase, uses saturated aqueous common salt (100mL) to wash once, and anhydrous magnesium sulfate is dried organic phase, removes by filter magnesium sulfateSolid, decompression desolvation, residue uses column chromatography purification to obtain (2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-hydroxylBase-2 methyl valeric acid tert-butyl ester (formula IX) (5.2 grams, 87%).
Embodiment 9:(2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-hydroxy-2-methyl valeric acid tert-butyl ester (formula IX)Preparation
20 grams (2R, 4R)-5-(1,1'-xenyl)-4-tert-butyl diphenyl siloxy-2 methyl valeric acid tert-butyl ester (formula VIII,R1=TBDPS) be dissolved in THF solution (200mL), stir lower reactant liquor cryosel bath and be cooled to 0 to 5 DEG C, in this reaction system, delaySlowly add TBAF solution (1MinTHF, 42mL). Dropwise rear reaction system and be naturally warming up to stirring at room temperature 12 hours. InsteadThe system of answering adds saturated NH4The Cl aqueous solution (200mL) cancellation reaction, system is used dichloromethane extraction (3 × 150mL). MergeOrganic phase, uses saturated aqueous common salt (150mL) to wash once, and anhydrous magnesium sulfate is dried organic phase, removes by filter magnesium sulfateSolid, decompression desolvation, residue uses column chromatography purification to obtain (2R, 4R)-5-([1,1'-biphenyl]-4-yl)-4-hydroxylBase-2 methyl valeric acid tert-butyl ester (formula IX) (10.6 grams, 90%).
Embodiment 10:(2R, 4S)-(5-([1,1'-biphenyl]-4-yl)-2 methyl valeric acid tert-butyl ester-4-yl)-pyrrolesAlkane-2, the preparation of 5-diketone (formula XII)
Under nitrogen protection, in reaction bulb, add successively 6.0 grams (2R, 4R)-5-(1,1'-xenyl)-4-hydroxy-2-methyl pentaTert-butyl acrylate (formula IX), THF (80mL), triphenylphosphine (7.0 grams) and succinimide (formula X) (2.1 grams), system stirs allAfter even, be cooled to 0-5 DEG C, then slowly drip the THF solution (10mL) of 4.6 grams of diethyl azodiformates, after dropwisingReaction system is warming up to room temperature reaction 6 hours naturally. System adds the 100mL shrend reaction of going out, and EtOAc extracts (3 × 100mL).Merge organic phase, use saturated aqueous common salt (100mL) to wash once, anhydrous magnesium sulfate is dried organic phase, removes by filter sulphurAcid magnesium solid, decompression desolvation, residue use column chromatography purification obtain (2R, 4S)-(5-([1,1'-biphenyl]-4-yl)-The 2 methyl valeric acid tert-butyl ester-4-yl)-pyrrolidines-2,5-diketone (formula XII) (5.1 grams, 69%).
Embodiment 11:(2R, 4S)-5-([1,1'-biphenyl]-4-yl)-2-methyl-4-phthaloyl imino-valeric acidThe preparation of the tert-butyl ester (formula XII)
Under nitrogen protection, in reaction bulb, add successively 7.2 grams (2R, 4R)-5-(1,1'-xenyl)-4-hydroxy-2-methyl pentaTert-butyl acrylate (formula IX), THF (100mL), triphenylphosphine (8.3 grams) and phthalimide (formula XI) (3.7 grams), systemAfter stirring, be cooled to 0-5 DEG C, then slowly drip the THF solution (20mL) of 6.5 grams of diisopropyl azodiformates, dripAfter adding, reaction system is warming up to room temperature reaction 6 hours naturally. System adds the 100mL shrend reaction of going out, EtOAc extraction (3 ×150mL). Merge organic phase, use saturated aqueous common salt (150mL) to wash once, anhydrous magnesium sulfate is dried organic phase, filtersRemove magnesium sulfate solid, decompression desolvation, residue uses column chromatography purification to obtain (2R, 4S)-5-([1,1'-biphenyl]-4-Base)-2-methyl-4-phthaloyl imino-valeric acid tert-butyl ester (formula XII) (6.2 grams, 62%).
Embodiment 12:(2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methyl methyl valerate hydrochloridePreparation
4.0 grams (2R, 4S)-(5-(1,1'-the xenyl)-2 methyl valeric acid tert-butyl ester-4-yl)-pyrrolidines-2,5-diketone(formula XII) is dissolved in 30mL methanol solvate, then in reaction system, adds 50mL hydrochloric acid, whole reaction system after addingHeating is back to raw material and disappears. Reaction system is cooled to room temperature naturally, and high vacuum is except desolventizing, and residue uses methyl alcohol/acetic acidEthyl ester be recrystallized (2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methyl methyl valerate hydrochloride (2.6 grams,81.5%)。
Embodiment 13:(2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methyl ethyl valerate hydrochloridePreparation
4.8 grams (2R, 4S)-5-(1,1'-xenyl)-2-methyl-4-phthaloyl imino-valeric acid tert-butyl ester (formulaXII) be dissolved in 50mL alcohol solvent, then in reaction system, add 65mL hydrochloric acid, after adding, whole reaction system addsHot reflux to raw material disappears. Reaction system is cooled to room temperature naturally, and high vacuum is except desolventizing, and residue uses ethanol/acetic acid secondEster be recrystallized (2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methyl ethyl valerate hydrochloride (2.4 grams,68%)。

Claims (6)

1. prepare the technique of (2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methyl valerate hydrochloride for one kind,(2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methyl valerate hydrochloride has following chemical structural formula:
Wherein R3Methyl or ethyl.
2. in claim 1, (2R, 4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methyl valerate hydrochloride is logicalCross formula XII and react and obtain under hydrochloric acid and alcohols solvent, formula XII has following structural formula:
Alcohols solvent comprises methyl alcohol or ethanol.
3. in claim 2, formula XII is through type IX and formula X(succinimide) or XI(phthalimide) occurMitsunobu reaction obtains, and the chemical structural formula of formula IX, formula X and XI is as follows:
The phosphonate reagent that Mitsunobu reaction is used is selected from triphenylphosphine or tri-n-butyl phosphine;
Mitsunobu reaction coupling reagent is selected from diethyl azodiformate (DEAD) or azoformic acid isopropyl ester(DIAD)。
4. in claim 3, formula IX is that through type VIII removes silica-based protecting group and obtains, and formula VIII chemical structural formula is as follows:
The solvent that this step reaction is used is selected from THF, EtOAc, Dioxane, CH3CN;
R in formula VIII1TBS or TBDPS protecting group.
5. in claim 4, formula VIII is RMgBr (formula VI) and (R)-2-fluoroform sulphonyl oxygen propionic acid prepared by through type VThe tert-butyl ester (formula VII) reaction obtains, and formula V, formula VI and formula VII have following chemical constitution:
In formula V, X is halogen, preferably chlorine;
In formula V, R1TBS or TBDPS;
In formula VI, X is halogen, preferably chlorine;
In formula VI, R1TBS or TBDPS;
In formula VII, R2Tf.
6. in claim 5, formula V obtains by the hydroxyl in TBSCl or TBDPSCl protection IV,
Formula IV has following chemical constitution:
In formula IV, X is halogen, preferably chlorine.
CN201610151805.5A 2016-03-17 2016-03-17 The preparation of LCZ696 key intermediates Active CN105601524B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610151805.5A CN105601524B (en) 2016-03-17 2016-03-17 The preparation of LCZ696 key intermediates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610151805.5A CN105601524B (en) 2016-03-17 2016-03-17 The preparation of LCZ696 key intermediates

Publications (2)

Publication Number Publication Date
CN105601524A true CN105601524A (en) 2016-05-25
CN105601524B CN105601524B (en) 2017-09-29

Family

ID=55981953

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610151805.5A Active CN105601524B (en) 2016-03-17 2016-03-17 The preparation of LCZ696 key intermediates

Country Status (1)

Country Link
CN (1) CN105601524B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017098430A1 (en) 2015-12-10 2017-06-15 Novartis Ag New process and intermediates
CN106966926A (en) * 2017-04-01 2017-07-21 沧州那瑞化学科技有限公司 A kind of preparation method of LCZ696 intermediates
WO2018007919A1 (en) 2016-07-05 2018-01-11 Novartis Ag New process for early sacubitril intermediates
CN107602399A (en) * 2016-07-11 2018-01-19 江西东邦药业有限公司 A kind of preparation method of enkephalinase inhibitor intermediate
WO2018033866A1 (en) 2016-08-17 2018-02-22 Novartis Ag New processes and intermediates for nep inhibitor synthesis
CN108047092A (en) * 2018-01-12 2018-05-18 重庆市碚圣医药科技股份有限公司 A kind of synthetic method of LCZ696 intermediates
WO2018116203A1 (en) 2016-12-23 2018-06-28 Novartis Ag New process for early sacubitril intermediates
CN110183357A (en) * 2019-06-13 2019-08-30 甘肃皓天医药科技有限责任公司 It is a kind of to be used to prepare preparation method of the Sha Ku than bent intermediate
US10668035B2 (en) 2018-02-07 2020-06-02 Novartis Ag Substituted bisphenyl butanoic ester derivatives as NEP inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104860894A (en) * 2015-06-10 2015-08-26 北京博全健医药科技有限公司 Method for preparing cardiotonic drug LCZ696
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
CN105254589A (en) * 2015-10-15 2016-01-20 上海博氏医药科技有限公司 Method for preparing midbody of heart failure medicine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
CN104860894A (en) * 2015-06-10 2015-08-26 北京博全健医药科技有限公司 Method for preparing cardiotonic drug LCZ696
CN105254589A (en) * 2015-10-15 2016-01-20 上海博氏医药科技有限公司 Method for preparing midbody of heart failure medicine

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017098430A1 (en) 2015-12-10 2017-06-15 Novartis Ag New process and intermediates
US11434192B2 (en) 2015-12-10 2022-09-06 Novartis Ag Process and intermediates
WO2018007919A1 (en) 2016-07-05 2018-01-11 Novartis Ag New process for early sacubitril intermediates
CN107602399A (en) * 2016-07-11 2018-01-19 江西东邦药业有限公司 A kind of preparation method of enkephalinase inhibitor intermediate
CN107602399B (en) * 2016-07-11 2020-09-25 江西东邦药业有限公司 Preparation method of enkephalinase inhibitor intermediate
WO2018033866A1 (en) 2016-08-17 2018-02-22 Novartis Ag New processes and intermediates for nep inhibitor synthesis
WO2018116203A1 (en) 2016-12-23 2018-06-28 Novartis Ag New process for early sacubitril intermediates
CN106966926B (en) * 2017-04-01 2018-10-19 沧州那瑞化学科技有限公司 A kind of preparation method of LCZ696 intermediates
CN106966926A (en) * 2017-04-01 2017-07-21 沧州那瑞化学科技有限公司 A kind of preparation method of LCZ696 intermediates
CN108047092A (en) * 2018-01-12 2018-05-18 重庆市碚圣医药科技股份有限公司 A kind of synthetic method of LCZ696 intermediates
US10668035B2 (en) 2018-02-07 2020-06-02 Novartis Ag Substituted bisphenyl butanoic ester derivatives as NEP inhibitors
US11426375B2 (en) 2018-02-07 2022-08-30 Novartis Ag Substituted bisphenyl butanoic ester derivatives as NEP inhibitors
CN110183357A (en) * 2019-06-13 2019-08-30 甘肃皓天医药科技有限责任公司 It is a kind of to be used to prepare preparation method of the Sha Ku than bent intermediate
CN110183357B (en) * 2019-06-13 2021-09-24 甘肃皓天医药科技有限责任公司 Preparation method for preparing Sacubitril intermediate

Also Published As

Publication number Publication date
CN105601524B (en) 2017-09-29

Similar Documents

Publication Publication Date Title
CN105601524A (en) Preparation method of LCZ696 key intermediate
CN105254589B (en) A method of preparing heart failure drugs intermediate
JP2010116331A (en) METHOD FOR PRODUCING alpha-SUBSTITUTED ESTERS
CN106995481A (en) Rakicidin A derivatives, its medical composition and its use
Ranu et al. Indium (III) chloride-catalyzed Michael addition of thiols to chalcones: a remarkable solvent effect
JP5646706B2 (en) Method for producing C-glycoside derivative
CN102617434B (en) Process for preparing Vildagliptin by one-pot method
JP2016204316A (en) Linker and carrier for solid phase synthesis of nucleic acid
CN101555267A (en) Synthesis method of clofarabine of nucleoside analogues
JP6212429B2 (en) Process for producing 1,3,4,5-tetracaffeoylquinic acid and intermediate compounds
JP7229539B2 (en) Production of highly lipophilic phosphoramidites
JP6459852B2 (en) Method for producing ether compound
US7049455B2 (en) Process for producing shogaols and intermediates for the synthesis thereof
KR101832238B1 (en) Novel sulfonyloxymethylphosphonate derivatives and process for preparing diisopropyl ((1-(trityloxymethyl)-cyclopropyl)oxy)methylphosphonate using the same
CN107011377A (en) A kind of preparation method of β oxo-phosphoric acids ester
US20220024960A1 (en) Improved synthesis of an expoxidation-catalyst
JPWO2004065346A1 (en) (-)-Tetrahydrolipstatin and method for producing the intermediate
CN109761868A (en) A kind of synthetic method of optical voidness cloprostenol
CN106674330A (en) 34-Dimethyl apratoxin A/E preparation method
CN104650160A (en) Novel synthesis method of capecitabine key intermediate 1,2,3-O-triacetyl-5-deoxy-D-ribose
CN101597226B (en) Method for synthesizing 6-hydroxyl-1-anisindione
JP2008512451A (en) Method for producing alkyl phosphinate
AU2014226533A1 (en) Isohexide monotriflates and process for synthesis thereof
CN105985370B (en) Prepare key intermediate and its application of limaprost
KR102418153B1 (en) Novel preparing method of inotodiol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 226123 No.18, Qinghua Road, Sanchang street, Haimen District, Nantong City, Jiangsu Province

Patentee after: Jiangsu Huiju Pharmaceutical Co.,Ltd.

Address before: 226123 No.18, Qinghua Road, Sanchang street, Haimen District, Nantong City, Jiangsu Province

Patentee before: Jiangsu Huiju Pharmaceutical Co.,Ltd.

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 226123 No.18, Qinghua Road, Sanchang street, Haimen District, Nantong City, Jiangsu Province

Patentee after: Jiangsu Huiju Pharmaceutical Co.,Ltd.

Address before: 226123 No. 18 Qinghua Road, three Factory Street, Haimen City, Nantong, Jiangsu

Patentee before: WISDOM PHARMACEUTICAL Co.,Ltd.